X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES TORRENT PHARMA SUVEN LIFESCIENCES/
TORRENT PHARMA
 
P/E (TTM) x 21.2 58.3 36.3% View Chart
P/BV x 4.1 5.5 75.2% View Chart
Dividend Yield % 0.6 0.9 59.2%  

Financials

 SUVEN LIFESCIENCES   TORRENT PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
TORRENT PHARMA
Mar-18
SUVEN LIFESCIENCES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2511,550 16.2%   
Low Rs1551,144 13.6%   
Sales per share (Unadj.) Rs49.1354.7 13.9%  
Earnings per share (Unadj.) Rs9.740.1 24.2%  
Cash flow per share (Unadj.) Rs11.464.2 17.7%  
Dividends per share (Unadj.) Rs1.5014.00 10.7%  
Dividend yield (eoy) %0.71.0 71.1%  
Book value per share (Unadj.) Rs60.3273.1 22.1%  
Shares outstanding (eoy) m127.28169.22 75.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.8 108.8%   
Avg P/E ratio x20.933.6 62.1%  
P/CF ratio (eoy) x17.821.0 84.9%  
Price / Book Value ratio x3.44.9 68.3%  
Dividend payout %15.434.9 44.2%   
Avg Mkt Cap Rs m25,825227,897 11.3%   
No. of employees `0001.114.7 7.3%   
Total wages/salary Rs m61311,353 5.4%   
Avg. sales/employee Rs Th5,832.64,083.0 142.9%   
Avg. wages/employee Rs Th571.5772.3 74.0%   
Avg. net profit/employee Rs Th1,153.8461.3 250.1%   
INCOME DATA
Net Sales Rs m6,25360,021 10.4%  
Other income Rs m2332,988 7.8%   
Total revenues Rs m6,48563,009 10.3%   
Gross profit Rs m1,98213,493 14.7%  
Depreciation Rs m2134,086 5.2%   
Interest Rs m463,085 1.5%   
Profit before tax Rs m1,9559,310 21.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,529 28.4%   
Profit after tax Rs m1,2376,781 18.2%  
Gross profit margin %31.722.5 141.0%  
Effective tax rate %36.727.2 135.3%   
Net profit margin %19.811.3 175.1%  
BALANCE SHEET DATA
Current assets Rs m5,62252,623 10.7%   
Current liabilities Rs m1,16852,022 2.2%   
Net working cap to sales %71.21.0 7,109.2%  
Current ratio x4.81.0 476.0%  
Inventory Days Days81120 68.1%  
Debtors Days Days3676 47.1%  
Net fixed assets Rs m3,32585,016 3.9%   
Share capital Rs m127846 15.0%   
"Free" reserves Rs m7,54745,376 16.6%   
Net worth Rs m7,67446,222 16.6%   
Long term debt Rs m1441,115 0.0%   
Total assets Rs m9,135142,432 6.4%  
Interest coverage x43.24.0 1,075.8%   
Debt to equity ratio x00.9 0.2%  
Sales to assets ratio x0.70.4 162.4%   
Return on assets %14.06.9 202.8%  
Return on equity %16.114.7 109.9%  
Return on capital %26.014.2 183.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06614,580 34.7%   
Fx outflow Rs m2,0013,600 55.6%   
Net fx Rs m3,06510,980 27.9%   
CASH FLOW
From Operations Rs m6998,942 7.8%  
From Investments Rs m-6-47,070 0.0%  
From Financial Activity Rs m-57734,174 -1.7%  
Net Cashflow Rs m116-3,655 -3.2%  

Share Holding

Indian Promoters % 63.4 71.5 88.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 8.8 414.8%  
Shareholders   37,287 26,511 140.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 20, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS